Perifusion of rat pituitaries: requirements for optimal GnRH-stimulated LH release.
Perifusion of rat hemipituitaries was used as an in vitro model for luteinizing hormone (LH) release in response to gonadotropin-releasing hormone (GnRH). LH release during continuous stimulation with GnRH (10(-7) M) was inhibited by EGTA (1.5 or 5 mM given 1 h prior to GnRH) or by D-600 (methoxyverapamil, 1 mM, given concomitantly with GnRH). These findings suggested that GnRH-stimulated LH release was a Ca2+-dependent process. Inhibition of LH release caused by Ca2+ chelation with EGTA was reversed when hemipituitaries were returned to medium without EGTA. Elevation of medium K+ (to 50 mM, without GnRH) stimulated Ca2+-dependent LH release during the 1st h. GnRH-stimulated LH release was 60% inhibited by cycloheximide (25 micrograms/ml) after the 1st h. LH release was not stimulated by dibutyryladenosine 3',5'-cyclic monophosphate (DBcAMP), although this cyclic nucleotide was shown to have biological activity and to enter pituitary cells as judged by its ability to stimulate prolactin release from the same tissue. The data suggest that optimal LH release in response to GnRH requires extracellular Ca2+ and depends on protein synthesis.
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000037:antagonists & inhibitors / Q000502:physiology; D003513:Cycloheximide / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D005711:Gallopamil / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology*; D066298:In Vitro Techniques; D007986:Luteinizing Hormone / Q000378:metabolism*; D010477:Perfusion; D010902:Pituitary Gland / Q000378:metabolism*; D051381:Rats
D007987:Gonadotropin-Releasing Hormone; D005711:Gallopamil; D004533:Egtazic Acid; D003994:Bucladesine; D007986:Luteinizing Hormone; D003513:Cycloheximide; D002118:Calcium